Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02989870
Title Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

hepatocellular carcinoma

Therapies

Bavituximab + Sorafenib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.